Fig.3 | Scientific Reports

Fig.3

From: Validation of the cancer-specific utility measure EORTC QLU-C10D using evidence from four lung cancer trials covering six country value sets

Fig.3

Sensitivity Analysis Summary of QLU-C10D for ECOG Performance status 0 (= fully active) vs. > 0 (restricted abilities) at Baseline across Three Lux-Lung Trials (LL1, LL3, LL8), and Relative Sensitivity compared to EQ-5D-3L, Using Utility Scores from Six Country-Specific Value Sets (Australia, Canada, Italy, the Netherlands, Poland, and the United Kingdom). Detailed results are presented in Appendix A; LL# Lux-Lung study number, k number of t-tests, 12 t-tests for each LL study (6 country value sets per utility measure); * p-values are Bonferroni-Holm corrected; ** Difference Cohen’s d = QLU-C10D minus EQ-5D-3L; Values > 0 favor QLU-C10D, < 0 favor EQ-5D-3L; *** Relative Efficiency: Values > 1 favor QLU-C10D, < 1 favor EQ-5D-3L.

Back to article page